Bicyclo Patents (Class 514/681)
-
Publication number: 20130137640Abstract: A composition includes a food ingredient or nutrient with safety and experience having been eaten for a long time and that shows a collagen enhancing activity. The food ingredient or nutrient of the composition includes a skin collagen enhancing agent that includes menaquinone-7 as an active ingredient. The composition including skin collagen enhancing agent can be administered percutaneously or orally as a drug, a cosmetic, or a supplement.Type: ApplicationFiled: October 3, 2012Publication date: May 30, 2013Applicant: J-OIL MILLS, INC.Inventor: J-OIL MILLS, INC.
-
Publication number: 20130123367Abstract: The present invention relates to vinylogous chalcone derivatives, in particular the compounds of formula (I) as described and defined herein, pharmaceutical compositions comprising these compounds, and their medical use, including their use in the treatment or prevention of cancer, in particular malignant hematological diseases/disorders.Type: ApplicationFiled: July 27, 2011Publication date: May 16, 2013Applicant: MEDIZINISCHE UNIVERSITAT WIENInventors: Thomas Erker, Gerda Brunhofer, Ulrich Jäger, Katrina Vanura, Verena Dirsch, Elke Heiss
-
Patent number: 8435497Abstract: The invention relates to pharmaceutical compositions containing combinations of formoterol and ciclesonide and the use of such pharmaceutical compositions in medicine, in particular, the prophylaxis and treatment of respiratory disease.Type: GrantFiled: June 9, 2004Date of Patent: May 7, 2013Assignee: Takeda GmbHInventors: Klaus Dietzel, Helgert Mueller
-
Publication number: 20130102650Abstract: The present invention relates to a compound having formula (I) wherein: R1 is chosen from the group consisting of: phenyl group, possibly substituted, —CH2—C6H4—R?1 group, R?1 being chosen from the group consisting of: H, —OH, halogen, alkyl, aryl, CHO, —CN, —NO2, —SR?, —OR?, —NR?R?, —CONR?R?, —COOR?, and —NHCOR?, R? and R? representing independently from each other H, an alkyl group or an aryl group, R?1 being preferably in para position, and —CH2—CO—R? group, R? representing an aryl or heteroaryl group, said aryl and heteroaryl groups being possibly substituted, R2 is chosen from the group consisting of: —OH and halogen, and R3, R4, R5 and R6 are in particular H, for its use for the prevention and/or the treatment of bacterial infections.Type: ApplicationFiled: April 8, 2011Publication date: April 25, 2013Inventors: Yap Jean-Bertrand Boum, II, Tamara Basta-Le-Berre, Ursula Liebl, Hannu Myllykallio
-
Publication number: 20130090355Abstract: The present invention provides methods of preventing or inhibiting tumor metastasis in a subject by administering a therapeutically effective amount of (1) a compound from a group of enumerated compounds, or a pharmaceutically acceptable salt thereof; (2) an agent that covalently modifies at least one cysteine residue of S100A4 protein; or (3) an agent that inhibits the interaction between S100A4 and myosin-IIA.Type: ApplicationFiled: April 28, 2011Publication date: April 11, 2013Applicant: ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITYInventor: Anne R. Bresnick
-
Publication number: 20130079396Abstract: The present invention relates to benzylidene indanones of general formula 1. The compounds exhibited tubulin polymerisation inhibition. A series of compounds 2-benzylidene 3-(3,4,5-trimethoxyphenyl) indanones having general formulae 1 were synthesized from gallic acid through a chemical process. 2-(3,4-Methylenedioxybenzylidine), 3-(3,4,5-trimethoxyphenyl), 4,5,6-trimethoxyindanone (8), a representative compound of this series possessing the molecular formulae C29H28O9, was synthesized from gallic acid and exhibits potent anticancer activity. Compound 8 was evaluated for acute oral activity in Swiss albino mice and found to be safe up to 300 mg/kg body weight. The anticancer activity of the compounds has been determined, in order to obtain new potent and cost effective molecules using an in vitro cytotoxicity assay.Type: ApplicationFiled: September 20, 2012Publication date: March 28, 2013Applicant: Council of Scientific and Industrial ResearchInventor: Council of Scientific and Industrial Research
-
Publication number: 20130059853Abstract: Novel biaryl compounds with phosphodiesterase inhibitory activity of the general formula (I), wherein R1, R2, R3, X, Y, Z1, Z2, Z3, and Z4 have the meanings defined herein, as well as their use as therapeutic agents in the treatment of inflammatory diseases and conditions.Type: ApplicationFiled: April 28, 2011Publication date: March 7, 2013Applicant: LEO PHARMA A/SInventors: Simon Feldbaek Nielsen, Anne Marie Horneman, Jesper Lau, Jens Christian Hojland Larsen
-
Publication number: 20120322889Abstract: The invention relates to the use of a compound according to formula (A) or formula (B), where R1, R4 and R5 are H, a glycoside, or an ester independently of each other, as a plant protection agent, wherein the plant protection agent comprises the compound, which is dissolved in a solvent at a concentration of 0.1 ?M to 2 mM.Type: ApplicationFiled: February 24, 2011Publication date: December 20, 2012Applicant: TECHNISCHE UNIVERSITAET WIENInventors: Karl Stich, Thilo Fischer, Christian Gosch
-
Publication number: 20120308658Abstract: The described invention provides a nonhuman animal model system for hemorrhagic brain conditions, methods for evaluating a substance for treating the hemorrhagic brain condition in a mammal, methods for treating hematoma expansion or recurrent rebleeding resulting from hemorrhagic brain conditions in a mammal, and pharmaceutical compositions for administration into or at a distance proximal to the hemorrhagic brain condition.Type: ApplicationFiled: July 13, 2012Publication date: December 6, 2012Inventor: R. Loch Macdonald
-
Publication number: 20120309845Abstract: The invention encompasses dosing regimens in which a subject is administered menatetrenone over a period of time to establish initial therapeutic baseline blood concentration of the menatetrenone followed by a maintenance therapy to maintain therapeutic blood concentrations. In other embodiments, the invention encompasses methods of treating acute myeloid leukemia in a subject in need thereof comprising administering to a subject a therapeutically effective dosing regimen of menatetrenone.Type: ApplicationFiled: June 1, 2011Publication date: December 6, 2012Applicant: NBI Pharmaceuticals, Inc.Inventors: John NEUSTADT, Steve PIECZENIK
-
Publication number: 20120283097Abstract: Provided are pesticidal compositions comprising 4,5-dihydroxyindan-1-one or derivatives thereof for protecting important crops against mites, fungi, and bacteria. The compositions may be manufactured by fractionating fungal extracts.Type: ApplicationFiled: September 13, 2010Publication date: November 8, 2012Applicant: YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEMInventors: Abraham Sztejnberg, Uri Gerson, Zahi Paz, Zohar Kerem, Izhak Bilkis
-
Publication number: 20120277180Abstract: Provided herein are methods and systems for identifying one or more cofactors such as vitamins for individuals based on the genetic makeup of the individual by detecting the presence or absence of at least one genetic variant, determining a predisposition to cofactor remediable condition, generating a personalized nutritional advice plan based on the genetic variant. Also provided herein are formulations of cofactors determined by the genetic make-up of the individual and methods of determining and producing these formulations.Type: ApplicationFiled: September 30, 2010Publication date: November 1, 2012Applicants: VITAPATH GENETICS, INC, THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: Nicholas Marini, Jasper Rine, Dennis Austin Gilbert, Bruce Cohen
-
Publication number: 20120269901Abstract: The present invention provides a method for treating cancer in a mammal comprising contacting the cancer cells with a compound which is a apogossypol, derivative.Type: ApplicationFiled: December 19, 2011Publication date: October 25, 2012Applicant: SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTEInventors: John C. Reed, Maurizio Pellecchia
-
Publication number: 20120264692Abstract: The present invention is based on the discovery of genetic polymorphisms that are associated with venous thrombosis. In particular, the present invention relates to nucleic acid molecules containing the polymorphisms, variant proteins encoded by such nucleic acid molecules, reagents for detecting the polymorphic nucleic acid molecules and proteins, and methods of using the nucleic acid and proteins as well as methods of using reagents for their detection.Type: ApplicationFiled: October 11, 2011Publication date: October 18, 2012Applicants: Leiden University Medical Center (LUMC) Acting on Behalf of Academic Hospital Leiden (AZL), CELERA CORPORATIONInventors: Lance BARE, James J. DEVLIN, Frits R. ROSENDAAL, Pieter H. REITSMA, Irene D. BEZEMER
-
Patent number: 8288444Abstract: A device for iontophoretically delivering a charged curcuminoid across the skin of an Alzheimer's Disease patient.Type: GrantFiled: June 29, 2011Date of Patent: October 16, 2012Assignee: Codman & Shurtleff, Inc.Inventors: Sean Lilienfeld, Thomas M DiMauro
-
Publication number: 20120259007Abstract: According to the invention there is provided a compound of formula (I): wherein R1, R2, R3 and n have meanings given in the description, or a pharmaceutically acceptable solvate, salt or prodrug thereof for use as an anticoagulant.Type: ApplicationFiled: December 22, 2010Publication date: October 11, 2012Applicant: HAOMA MEDICA LIMITEDInventors: Stephen Hodges, Robin Soper
-
Publication number: 20120238450Abstract: The present invention relates to novel c2-phenyl-substituted cyclic ketoenols, to a plurality of processes for their preparation and to their use as pesticides as herbicides.Type: ApplicationFiled: April 25, 2012Publication date: September 20, 2012Applicant: Bayer AktiengesellschaftInventors: Michael Ruther, Hermann Hagemann, Udo Schneider, Markus Dollinger, Peter Dahmen, Ulrike Wachendorff-Neumann, Reiner Fischer, Alan Graff, Thomas Bretschneider, Christoph Erdelen, Mark Wilhelm Drewes, Dieter Feucht, Folker Lieb
-
Publication number: 20120238637Abstract: The invention refers to an isolated extract of walnuts of high efficiency and stability over time useful for the manufacture of a medicament for the treatment of viral, fungal and bacterial diseases, which is characterized in that it is obtained from a process comprising: i) collecting unripe walnut fruits as raw material; ii) preparing the raw material for the extraction, iii) freezing the raw material prepared in the previous step; iv) drying; v) extracting in a time lower than 10 minutes; vi) filtration; and vii) final packaging. The invention also refers to its use for manufacturing a medicament for the treatment of bacterial, fungal and viral diseases and to a composition comprising it.Type: ApplicationFiled: May 30, 2012Publication date: September 20, 2012Applicant: Hartington Business, S.L.Inventor: Vakhtang MTCHEDLIDZE
-
Publication number: 20120207707Abstract: Methods of increasing production, stability or activity of a target polypeptide are provided herein. The method includes increasing the level of an antioxidant in a cell comprising a polynucleotide encoding the target polypeptide. Also provided are cells and transgenic organisms produced using the methods described herein. Methods of treating a subject with a condition treatable by administration of the target polypeptide are also disclosed. Finally methods and compositions for transiently increasing antioxidants in plant cells are provided.Type: ApplicationFiled: October 22, 2010Publication date: August 16, 2012Inventors: Maureen C. Dolan, Argelia Lorence, Giuliana Medrano
-
Publication number: 20120208893Abstract: Nutritional compositions and methods of making and using the nutritional compositions are provided. In a general embodiment, the present disclosure provides a nutritional composition including exogenous vitamin K2. The nutritional compositions may further include an additional component selected from the group consisting of phosphorus, magnesium, zinc, iron, copper, manganese, calcium, vitamin D, osteopontin and combinations thereof.Type: ApplicationFiled: September 1, 2010Publication date: August 16, 2012Applicant: NESTEC S.A.Inventors: Douglas Richard Bolster, Zamzam Kabiry Roughead
-
Publication number: 20120196852Abstract: The invention is directed towards novel naphthoquinone and naphthothiazole compounds, and methods of treating disorders related to MetAP, including tuberculosis and bacterial infection, using various naphthoquinone, hydroxyquinonline, and naphthothiazole compounds.Type: ApplicationFiled: August 5, 2010Publication date: August 2, 2012Applicant: THE JOHNS HOPKINS UNIVERSITYInventors: Jun O. Liu, Omonike Arike Olaleye, Shridhar Bhat
-
Publication number: 20120189719Abstract: Disclosed are an Schisandrae fructus extract for inhibition or prevention of influenza and its application, wherein the Schisandrae fructus extract is obtained by water, methanol, or ethanol extraction process and the extract comprises compounds such as schisandrone, benzoylgomisin P, wulignan A1, epigomisin O, epiwulignan A1, and tigloylgomisin P. The extracts and purified compounds of Schisandrae fructus has anti-influenza virus H1N1 and H1N1-TR (a Tamiflu drug resistant virus strain) activities, therefore the extracts and the purified compounds of Schisandrae fructus can be applied as an inhitibory agent of a pharmaceutical composition for treatment or prevention agent for influenza infection.Type: ApplicationFiled: November 17, 2011Publication date: July 26, 2012Applicant: NATIONAL DEFENSE MEDICAL CENTERInventors: WEN-LIANG CHANG, CHEN-WEN YAO, CHI-HONG CHU, AN-RONG LEE, ANN CHEN, WEN-HSIN HUANG, KUO-YUAN HWA, CHIAO-YING CHIEN, CHIEN-YI PAI
-
Publication number: 20120149780Abstract: The invention relates to Vitamin K, its derivatives and combinations to increase the energy levels in diverse disease states and life style disorders, which are characterized by low energy level due to inadequate VO2max, and pO2 and low availability of ATP molecules. VO2max, peak oxygen uptake, is intimately connected to several diseases and life style disorders such as Metabolically Obese but Normal Weight (MONW), Overweight/Obese, diabetes mellitus, coronary artery disease, hypertension, cerebral vascular insufficiency, immune deficient states, cancer, aging-related disorders, reduced cardiopulmonary reserves and muscular fitness in athletics, high altitude climbing and exercise. The invention discloses that innovative blends of components that, in unique combination, synergistically bestow enhancement of VO2max leading to higher energy level, less fatigability and energy adaptations to stressful stimuli in humans and animals.Type: ApplicationFiled: March 12, 2010Publication date: June 14, 2012Inventors: Dilip S Mehta, Anselm De Souza, Ashok B. Vaidya, Rama A. Vaidya, Dale Kriz, Kiran Krishnan
-
Publication number: 20120130147Abstract: Compounds of the formula (I), in which R1, R2, R3, R4, and q have the meanings indicated in Claim 1, can be employed, inter alia, for the treatment of tumours.Type: ApplicationFiled: January 25, 2012Publication date: May 24, 2012Inventors: Dirk FINSINGER, David Bruge, Hans-Peter Buchstaller, Ulrich Emde, Kai Schiemann, Wolfgang Staehle, Christiane Amendt, Nina Heiss, Frank Zenke
-
Publication number: 20120122877Abstract: The present invention is antibiotic compositions having the ability to disrupt a MazEF complex in S. aureus. The compositions also have the ability to inhibit growth of S. aureus and as such are useful as antibiotic compounds.Type: ApplicationFiled: July 1, 2010Publication date: May 17, 2012Applicant: TRUSTEES OF DARTMOUTH COLLEGEInventors: Ambrose Cheung, Zhibiao Fu
-
Publication number: 20120077869Abstract: Phosphotyrosine phosphatase (PTP) encoded by PF13_0027 is a desirable drug target for the human malaria parasite Plasmodium falciparum. This PTP is critical for intraerythrocytic parasite development and invasion of erythrocytes by malaria merozoites. Mutation of the PF13_0027 gene or blocking expression of PTP function to create a PTP-null parasite severely attenuates the malaria parasite's ability to survive, making the PTP-null parasite suitable as an attenuated blood-stage parasite vaccine.Type: ApplicationFiled: September 20, 2011Publication date: March 29, 2012Applicant: UNIVERSITY OF SOUTH FLORIDAInventors: John H. Adams, Bharath Balu, Steven P. Maher, Christopher O. Campbell, Roman Manetsch
-
Publication number: 20120041072Abstract: A compound having inhibitory activity on the binding of a substance ? to a PTGS suppressor protein, wherein the substance ? has a property of inducing PTGS and a property of binding to the PTGS suppressor protein and shows a decrease in the property of inducing PTGS upon binding to the PTGS suppressor protein.Type: ApplicationFiled: June 15, 2011Publication date: February 16, 2012Applicants: HOKKAIDO UNIVERSITY, NIPPON SODA CO., LTD.Inventors: Shinsuke Sano, Takako Fukagawa, Hirokazu Yamada, Chikara Masuta, Hanako Shimura
-
Publication number: 20110281883Abstract: The present invention relates to the use of compounds of Formula (I) wherein R1, R2, R3, R4, R5, R6, R7, r, Y and G have the meanings given above as insecticides and/or acaricides and/or fungicides.Type: ApplicationFiled: January 14, 2010Publication date: November 17, 2011Applicant: Bayer Cropscience AGInventors: Reiner Fischer, Stefan Lehr, Arnd Voerste
-
Publication number: 20110206770Abstract: Atovaquone or a pharmaceutically acceptable salt thereof having a particle size diameter range with a D90 of between greater than 3 to about 10 ?m.Type: ApplicationFiled: February 4, 2009Publication date: August 25, 2011Applicant: Alphapharm Pty. Ltd.Inventors: Brett Antony Mooney, Panaglotis Keramidas
-
Patent number: 7985776Abstract: A method of delivering a curcuminoid to a patient, which includes iontophoretically delivering a charged curcuminoid across the skin of an Alzheimer's Disease patient.Type: GrantFiled: June 27, 2008Date of Patent: July 26, 2011Assignee: Codman & Shurtleff, Inc.Inventors: Sean Lilienfeld, Thomas M. Di Mauro
-
Patent number: 7976876Abstract: The present invention relates to an anti-bacterial, anti-virus, and anti-fungus composition, its preparation and use. The composition of the present invention mainly includes the following three ingredients in an adequate ratio: (A) a metal compound having a catalytic function; (B) a mixture of a coenzyme having reducing ability and a quinone, and (C) an additive. The anti-bacterial, anti-virus, and anti-fungus composition of the present invention is capable of destroying viruses as well as killing bacterial and fungi. Therefore, the composition can be formulated as an aerosol and a film for applying to protection devices such as respirators, masks, gloves, filters, condoms, etc. The present composition can also be used in household, vehicle, hospital, school, restaurant, hotel, internet coffee shop for applying to filter of air-conditioner, tap, stool, interior of elevator and its keyboard.Type: GrantFiled: September 29, 2008Date of Patent: July 12, 2011Assignee: Well-Being Biochemical Corp.Inventors: Jih-ru Hwu, Shwu-chen Tsay
-
Patent number: 7968127Abstract: A formulation or preparation for treating and preventing arterial and venous thrombi is provided. This preparation includes a non-metal containing photodynamic dye and a fat soluble vitamin. A method of administration for treatment and prophylaxis of arterial and venous thrombi is also provided. This method includes steps of: combining a non-metal containing photodynamic dye and a fat soluble vitamin; combining the non-metal containing photodynamic dye and fat soluble vitamin with a sodium solution; and administering the combination of non-metal containing photodynamic dye, fat soluble vitamin, and sodium solution as an intravenous drip.Type: GrantFiled: July 28, 2008Date of Patent: June 28, 2011Inventor: David E. Winslow
-
Publication number: 20110124610Abstract: There is disclosed herein a method of increasing bone density, maintaining bone density and/or inhibiting loss of bone density and/or reducing osteochondral defects in an animal comprising administering to an animal an effective amount of a composition containing: vitamin K1, vitamin K2 or a mixture of vitamin K1 and vitamin K2, together with a physiologically acceptable carrier, incipient and/or diluent. Various compositions including vitamin K are also disclosed.Type: ApplicationFiled: June 2, 2009Publication date: May 26, 2011Inventors: John Ray Biffin, Hubertus Leonardus Regtop
-
Patent number: 7943160Abstract: Certain embodiments of the methods and compositions of matter disclosed herein relate to: “simultaneous” control of rodents and at least one insect pest (e.g., cockroach, ant, tick) using the same bait; control of ticks by orally administering to mammals a diet composition comprising fipronil; enhancing insecticide efficacy through use of a diet composition that comprises a Generation-I rodenticide and an insecticide; use of imidacloprid in a diet composition orally administerable to mammals in an uncontrolled setting; and use of at least one insecticide to enhance the efficacy of a rodenticide.Type: GrantFiled: October 25, 2005Date of Patent: May 17, 2011Assignee: Scimetrics Limited Corp.Inventors: Jeff N. Borchert, Richard M. Poché
-
Publication number: 20110111057Abstract: The present invention provides a method for treating cancer in a mammal comprising contacting the cancer cells with a compound which is a apogossypol, derivative.Type: ApplicationFiled: October 7, 2010Publication date: May 12, 2011Inventors: John C. Reed, Maurizio Pellecchia
-
Patent number: 7939568Abstract: The present invention is related to the use of a composition having an adequate pharmaceutical or cosmetic carrier or diluent and a sufficient amount of vitamin K1 oxide or its derivative for the treatment and/or the prevention of mammal dermatological lesions. The present invention is also related to a cosmetic composition having an adequate cosmetic carrier, phospholipids and vitamin K1 oxide or its derivative.Type: GrantFiled: January 20, 2004Date of Patent: May 10, 2011Assignee: Auriga International S.A.Inventor: Alfred Marchal
-
Publication number: 20110059972Abstract: 1,4 naphthoquinones derivatives, of formula (I) wherein A is selected from the following rings: their preparation and their application as antimalarial agentsType: ApplicationFiled: March 25, 2009Publication date: March 10, 2011Applicant: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUEInventors: Elisabeth Davioud-Charvet, Tobias Muller, Holger Bauer, R. Heiner Schirmer
-
Publication number: 20110059159Abstract: Methods for rapidly obtaining a nanoscale apolipoprotein bound phospholipid bilayer (NABB) associated with at least one membrane protein are provided. Also disclosed are methods for rapidly obtaining a NABB not associated with membrane proteins. Immunogenic compositions comprising NABBs with native conformational epitopes are also provided along with their methods of use.Type: ApplicationFiled: January 30, 2009Publication date: March 10, 2011Applicant: THE ROCKEFELLER UNIVERSITYInventors: Thomas P. Sakmar, Thomas Huber, Sourabh Banerjee
-
Patent number: 7897640Abstract: Medicaments containing shikonin compounds and salts thereof including shikonin and alkannin are used for treatment of virus infections, mycoplasma infections and malignant tumor.Type: GrantFiled: September 26, 2007Date of Patent: March 1, 2011Assignee: Beijing JBC Chinese Traditional Medicine Science and Technology Develop Co. LtdInventor: Feixin Wang
-
Publication number: 20110039701Abstract: The invention relates to novel compounds of the formula (I) in which X, Y, Z, A, B and G have the meanings given above, to a plurality of processes and intermediates for their preparation and to their use as pesticides and/or herbicides. Moreover, the invention relates to selective herbicidal compositions comprising, firstly, the phenyl-substituted bicyclooctane-1,3-dione derivates 33 and, secondly, a crop plant compatibility-improving compound. The present invention furthermore relates to increasing the activity of crop protection compositions comprising in particular phenyl-substituted bicyclooctane-1,3-dione derivates by adding ammonium salts or phosphonium salts and, if appropriate, penetrants, to the corresponding compositions, to processes for their preparation and to their use in crop protection as insecticides and/or acaricides and/or for preventing unwanted plant growth.Type: ApplicationFiled: March 30, 2010Publication date: February 17, 2011Applicant: Bayer CropScience AGInventors: Alfred ANGERMANN, Guido Bojack, Reiner Fischer, Stefan Lehr, Jan Dittgen, Dieter Feucht, Isolde Häuser-Hahn, Christopher Hugh Rosinger, Arnd Voerste
-
Patent number: 7851510Abstract: The present invention relates to compounds of general formula (1): in which, independently of each other, R1 and R2 represent: —OH, or —CH2—O—R3, or —CH2—S—R3, or R3, R4, R5 and R6 representing, independently of each other, —H or a carbon-containing group with 1 to 10 carbon atoms, saturated or unsaturated, optionally substituted with one or more heteroatomic groups. The invention also relates to pharmaceutical compositions containing these compounds, and their uses, in particular in the context of the treatment of cancer.Type: GrantFiled: January 6, 2005Date of Patent: December 14, 2010Assignees: Centre National de la Recherche Scientifique (C.N.R.S.), Institut National de la Sante et de la Recherche Medicale (I.N.S.E.R.M)Inventors: Vi-Thuy Dao, Jean De Gunzburg, Robert Michelot, Oliver Christophe De Mil
-
Publication number: 20100305095Abstract: The present invention relates to, inter alia, the use of a compound capable of inhibiting 4-hydroxyphenylpyruvate dioxygenase (HPPD) in an animal in the manufacture of a medicament for use in the treatment and/or prevention of depression. The invention also provides for the use of a compound capable of inhibiting HPPD in an animal in the manufacture of a medicament for use in the treatment of the withdrawal symptoms associated with an addictive drug which causes dopamine dependant associative learning disorders in said animal. In a particular embodiment said HPPD inhibitor is selected from the group consisting of the compound depicted as compound 1; 2; and 3.22.Type: ApplicationFiled: August 18, 2006Publication date: December 2, 2010Inventors: Kim Zachary Travis, John Posner
-
Patent number: 7829555Abstract: The invention provides a method of targeting a drug to areas of hypoxic and/or ischemic tissue within the body in which the desired drug species is linked to a non-cytotoxic bioreductive carrier. Also provided by the invention are novel bioreductive conjugates comprising a non-cytotoxic bioreductive moiety with linked-thereto at least one therapeutic agent. The compounds of the invention are particularly suitable for the treatment of rheumatoid arthritis and other arthritic conditions, diabetes, atherosclerosis, stroke, sepsis, Alzheimer's disease and other neurological disorders, cancer, kidney disease, digestive diseases, liver disease, chronic periodontitis or ischemia following tissue transplantation.Type: GrantFiled: February 13, 1998Date of Patent: November 9, 2010Assignee: The University of ManchesterInventors: David Blake, Declan Naughton, Ged Adams, Margaret Adams, legal representative, Ian Stratford, Christopher Morris, Mohammed Jaffar, Matthew Naylor
-
Publication number: 20100279963Abstract: Derivatives of dicarbonyl compounds having antitumor and antibiotic activity which can be used as anticancer agents.Type: ApplicationFiled: July 1, 2010Publication date: November 4, 2010Applicant: Abraxis BioScience, LLCInventors: Chunlin Tao, Qinwei Wang, Vuong Trieu, Neil Desai, Patrick Soon-Shiong
-
Publication number: 20100247462Abstract: Processes for synthesizing resveratrol-based oligomers are provided. In addition, resveratrol-based oligomer compounds free of plant extract are provided.Type: ApplicationFiled: September 17, 2008Publication date: September 30, 2010Inventors: Scott Alan Snyder, Steven P. Breazzano, Audrey G. Ross, Yunqing Lin, Alexandros L. Zografos
-
Publication number: 20100241059Abstract: A device for treating a skin condition is provided. The device comprises a delivery system for administering a composition to the skin disorder. The delivery system includes an electrode for delivering a composition to the skin of a person and a counter electrode. The device also includes a drainage system which includes a channel for removing material from a person's skin and a pump in communication with the channel The device further includes a control system for powering and controlling the electrode system.Type: ApplicationFiled: October 23, 2008Publication date: September 23, 2010Applicant: SKINTREET, LLCInventors: Marina Prushinskaya, Leonid Kaplan
-
Publication number: 20100216835Abstract: The present invention provides compositions and methods for modulating bacterial quorum sensing using antagonist or agonist compounds. Further, the present invention provides methods of treating or preventing microbial damages and diseases, in particular for diseases where there is an advantage in inhibiting quorum sensing regulated phenotypes of pathogens.Type: ApplicationFiled: February 25, 2010Publication date: August 26, 2010Inventors: Jo E. Handelsman, Bradley R. Borlee
-
Publication number: 20100210524Abstract: The invention provides a compound of formula (I) or a pharmaceutically acceptable ester, amide, solvate or salt thereof, including a salt of such an ester or amide, and a solvate of such an ester, amide or salt, wherein W, X, Y, Z, R1, R2, R7, R8, R9, R10, R11, R12, R13, R14, R15 and R16 are as defined in the specification. The invention also provides also provides the use of such compounds in the treatment or prophylaxis of a condition associated with a disease or disorder associated with estrogen receptor activity.Type: ApplicationFiled: July 21, 2008Publication date: August 19, 2010Inventors: Theresa Apelqvist, Joakim Löfstedt, Thomas Norin, Mattias Wennerstål, Xiongyu Wu, Lars Hagberg
-
Publication number: 20100190732Abstract: This invention relates to the use of pterosin compounds of formula I for treating diabetes including type I and type II. Also disclosed is the use of the pterosin compounds for treating obesity.Type: ApplicationFiled: January 26, 2010Publication date: July 29, 2010Applicants: Taipei Medical University, National Taiwan University, National Tsing Hua University, DCB-USA, LLCInventors: Feng-Lin Hsu, Shing-Hwa Liu, Biing-Jiun Uang
-
Publication number: 20100130618Abstract: The present invention is related to the therapeutic uses of vitamin K, its analogues and derivatives in a diverse array of disease conditions. Vitamin K improves blood perfusion and ameliorates hypoxia in prevention and treatment of conditions such as chronic venous insufficiency manifestations, post thrombotic syndrome, skin conditions related to melanization, hyperpigmentation, Paresthesiae, oedema, varicose veins, VTE and cramps. The invention also provides pharmaceutical compositions comprising vitamin K, its analogues, derivatives or vitamin K-like compounds either alone or in combination with one or more therapeutically effective active agents for the diseases/conditions of venous, nerves and lymph, that are encompassed by this invention.Type: ApplicationFiled: July 21, 2008Publication date: May 27, 2010Inventors: Ashok B Vaidya, Dilip S. Mehta, Anselm de Souza, Rama A. Vaidya